Dronabinol is in clinical development for the treatment of spasticity caused by multiple sclerosis (MS). MS is a long-term condition that affects the brain and spinal cord, causing a range of symptoms including spasticity. Spasticity is when the muscles become stiff and resistant to movement, which can be extremely painful. There are currently limited treatment options for patients with spasticity caused by MS.
Dronabinol, administered orally, is a synthetic (artificial) form of the psychoactive component of cannabis, which means it can cause changes to cognitive/emotional processes and reduces pain. Dronabinol may reduce spasticity although the precise mechanism for this effect has not been elucidated. If licensed, dronbionol will offer an additional treatment option for adults with spasticity caused by MS.
Levodopa, carbidopa monohydrate and entacapone intestinal gel (LECIG, TRICEL, Lecigon) is in development to treat severe motor fluctuations in advanced Parkinson’s disease (PD). PD is a progressive neurological disease caused by a loss of nerve cells in a particular part of the brain that results in decreased levels of the chemical messenger dopamine. This results …